Symbols / VOR $15.71 -5.30% Vor Biopharma Inc.

Healthcare • Biotechnology • United States • NMS
VOR Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Fundamentals
Scroll to Statements
Market Cap 767.39M Enterprise Value 315.19M Income -695.98M Sales — Book/sh -8.10 Cash/sh 9.32
Dividend Yield — Payout 0.00% Employees 76 IPO — P/E — Forward P/E -4.24
PEG — P/S — P/B -1.94 P/C — EV/EBITDA -0.93 EV/Sales —
Quick Ratio 18.09 Current Ratio 18.20 Debt/Eq — LT Debt/Eq — EPS (ttm) -70.50 EPS next Y -3.70
EPS Growth — Revenue Growth — Earnings 2026-05-15 ROA -70.41% ROE — ROIC —
Gross Margin 0.00% Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 48.85M Shs Float 36.52M Short Float 12.67%
Short Ratio 5.43 Short Interest — 52W High 65.80 52W Low 2.62 Beta 1.92 Avg Volume 984.73K
Volume 1.08M Target Price $37.50 Recom Strong_buy Prev Close $16.59 Price $15.71 Change -5.30%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$37.50
Mean price target
2. Current target
$15.71
Latest analyst target
3. DCF / Fair value
$-66.58
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$15.71
Low
$15.00
High
$50.00
Mean
$37.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-15 main HC Wainwright & Co. Buy → Buy $31
2026-03-31 main Wedbush Neutral → Neutral $15
2026-03-30 init Jefferies — → Buy $50
2026-03-19 init Wells Fargo — → Overweight $30
2026-01-09 init Citigroup — → Buy $50
2025-12-19 main JP Morgan Overweight → Overweight $40
2025-12-17 init TD Cowen — → Buy —
2025-12-09 init JP Morgan — → Overweight $43
2025-11-14 main HC Wainwright & Co. Buy → Buy $32
2025-10-29 main HC Wainwright & Co. Buy → Buy $55
2025-10-15 up Baird Neutral → Outperform $64
2025-08-14 reit HC Wainwright & Co. Buy → Buy $3
2025-06-30 up HC Wainwright & Co. Neutral → Buy $3
2025-06-27 main Baird Neutral → Neutral $1
2025-06-26 reit Wedbush Neutral → Neutral $0
2025-05-09 down JMP Securities Market Outperform → Market Perform $6
2025-05-09 down HC Wainwright & Co. Buy → Neutral —
2025-03-21 reit Oppenheimer Outperform → Outperform $8
2025-03-21 main Stifel Buy → Buy $5
2025-03-21 main HC Wainwright & Co. Buy → Buy $13
News
RSS: Latest VOR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-15 RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security — 737,989 $15.97 $11,883,340
2026-04-06 RA CAPITAL MANAGEMENT, L.P. Director and Beneficial Owner of more than 10% of a Class of Security — 849,257 $16.51 $14,518,963
2025-10-30 RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security — 400,408 $25.12 $10,368,938
2025-10-27 RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security — 221,166 $28.01 $6,204,863
2025-10-21 RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security — 117,050 $28.11 $3,433,992
2025-10-21 REPROGRAMMED INTERCHANGE LLC Beneficial Owner of more than 10% of a Class of Security — 37,533 $30.05 $1,133,103
2025-10-17 RA CAPITAL HEALTHCARE FUND,L.P. Director and Beneficial Owner of more than 10% of a Class of Security — 464,025 $29.12 $13,707,361
2025-10-16 REPROGRAMMED INTERCHANGE LLC Beneficial Owner of more than 10% of a Class of Security — 73,676 $30.45 $2,348,744
2025-10-14 REPROGRAMMED INTERCHANGE LLC Beneficial Owner of more than 10% of a Class of Security — 96,657 $30.32 $3,003,706
2025-10-09 REPROGRAMMED INTERCHANGE LLC Beneficial Owner of more than 10% of a Class of Security — 124,146 $31.92 $4,116,369
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
371.64
+206.67%
121.19
-3.85%
126.04
+34.92%
93.42
Research And Development
321.53
+244.58%
93.31
-1.07%
94.31
+46.11%
64.55
Selling General And Administration
50.11
+79.77%
27.88
-12.12%
31.72
+9.88%
28.87
General And Administrative Expense
50.11
+79.77%
27.88
-12.12%
31.72
+9.88%
28.87
Other Gand A
50.11
+79.77%
27.88
-12.12%
31.72
+9.88%
28.87
Total Expenses
371.64
+206.67%
121.19
-3.85%
126.04
+34.92%
93.42
Operating Income
-371.64
-206.67%
-121.19
+3.85%
-126.04
-34.92%
-93.42
Total Operating Income As Reported
-371.64
-206.67%
-121.19
+3.85%
-126.04
-34.92%
-93.42
EBITDA
-368.75
-213.42%
-117.66
+3.99%
-122.54
-34.82%
-90.89
Normalized EBITDA
-34.40
+70.77%
-117.66
+3.99%
-122.54
-34.82%
-90.89
Reconciled Depreciation
2.89
-18.17%
3.53
+1.03%
3.49
+38.30%
2.52
EBIT
-371.64
-206.67%
-121.19
+3.85%
-126.04
-34.92%
-93.42
Total Unusual Items
-334.36
—
—
—
Total Unusual Items Excluding Goodwill
-334.36
—
—
—
Net Income
-695.98
-495.29%
-116.91
+0.81%
-117.86
-27.98%
-92.09
Pretax Income
-695.98
-495.29%
-116.91
+0.81%
-117.86
-27.98%
-92.09
Net Non Operating Interest Income Expense
5.87
+37.39%
4.27
-47.74%
8.17
+517.30%
1.32
Net Interest Income
5.87
+37.39%
4.27
-47.74%
8.17
+517.30%
1.32
Interest Income Non Operating
5.87
+37.39%
4.27
-47.74%
8.17
+517.30%
1.32
Interest Income
5.87
+37.39%
4.27
-47.74%
8.17
+517.30%
1.32
Other Income Expense
-330.21
—
—
—
Other Non Operating Income Expenses
4.15
—
—
—
Gain On Sale Of Security
-334.36
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-695.98
-495.29%
-116.91
+0.81%
-117.86
-27.98%
-92.09
Net Income From Continuing Operation Net Minority Interest
-695.98
-495.29%
-116.91
+0.81%
-117.86
-27.98%
-92.09
Net Income From Continuing And Discontinued Operation
-695.98
-495.29%
-116.91
+0.81%
-117.86
-27.98%
-92.09
Net Income Continuous Operations
-695.98
-495.29%
-116.91
+0.81%
-117.86
-27.98%
-92.09
Normalized Income
-361.62
-209.31%
-116.91
+0.81%
-117.86
-27.98%
-92.09
Net Income Common Stockholders
-695.98
-495.29%
-116.91
+0.81%
-117.86
-27.98%
-92.09
Diluted EPS
—
-34.03
+2.77%
-35.00
+24.89%
-46.60
Basic EPS
—
-34.03
+2.77%
-35.00
+24.89%
-46.60
Basic Average Shares
—
3.44
+2.26%
3.36
+69.89%
1.98
Diluted Average Shares
—
3.44
+2.26%
3.36
+69.89%
1.98
Diluted NI Availto Com Stockholders
-695.98
-495.29%
-116.91
+0.81%
-117.86
-27.98%
-92.09
Preferred Stock Dividends
—
—
—
—
Line Item Trend 2024-12-31 2021-12-31
Total Assets
142.89
—
Current Assets
96.51
—
Cash Cash Equivalents And Short Term Investments
91.93
—
Cash And Cash Equivalents
81.95
—
Other Short Term Investments
9.98
—
Prepaid Assets
4.20
—
Other Current Assets
0.38
—
Total Non Current Assets
46.38
—
Net PPE
41.59
—
Gross PPE
52.80
—
Accumulated Depreciation
-11.21
—
Properties
—
0.00
Machinery Furniture Equipment
1.05
—
Construction In Progress
0.04
—
Other Properties
51.71
—
Leases
—
0.06
Other Non Current Assets
4.80
—
Total Liabilities Net Minority Interest
46.23
—
Current Liabilities
18.61
—
Payables And Accrued Expenses
8.19
—
Payables
1.50
—
Accounts Payable
1.50
—
Current Accrued Expenses
6.68
—
Pensionand Other Post Retirement Benefit Plans Current
5.85
—
Current Debt And Capital Lease Obligation
4.21
—
Current Capital Lease Obligation
4.21
—
Other Current Liabilities
0.36
—
Total Non Current Liabilities Net Minority Interest
27.61
—
Long Term Debt And Capital Lease Obligation
27.61
—
Long Term Capital Lease Obligation
27.61
—
Stockholders Equity
96.66
—
Common Stock Equity
96.66
—
Capital Stock
0.01
—
Common Stock
0.01
—
Preferred Stock
0.00
—
Share Issued
6.24
—
Ordinary Shares Number
6.24
—
Treasury Shares Number
0.00
-100.00%
0.01
Additional Paid In Capital
553.62
—
Retained Earnings
-456.99
—
Gains Losses Not Affecting Retained Earnings
0.02
—
Other Equity Adjustments
0.02
—
Total Equity Gross Minority Interest
96.66
—
Total Capitalization
96.66
—
Working Capital
77.89
—
Invested Capital
96.66
—
Total Debt
31.83
—
Capital Lease Obligations
31.83
—
Net Tangible Assets
96.66
—
Tangible Book Value
96.66
—
Derivative Product Liabilities
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-142.71
-43.20%
-99.66
+0.63%
-100.29
-17.79%
-85.14
Cash Flow From Continuing Operating Activities
-142.71
-43.20%
-99.66
+0.63%
-100.29
-17.79%
-85.14
Net Income From Continuing Operations
-695.98
-495.29%
-116.91
+0.81%
-117.86
-27.98%
-92.09
Depreciation Amortization Depletion
2.89
-18.17%
3.53
+1.03%
3.49
+38.30%
2.52
Depreciation
2.89
-18.17%
3.53
+1.03%
3.49
+38.30%
2.52
Depreciation And Amortization
2.89
-18.17%
3.53
+1.03%
3.49
+38.30%
2.52
Other Non Cash Items
518.02
+10176.23%
5.04
+6.64%
4.73
+32.11%
3.58
Stock Based Compensation
18.91
+92.06%
9.85
-26.31%
13.36
+24.94%
10.70
Operating Gains Losses
3.30
+18450.00%
-0.02
—
—
Gain Loss On Sale Of PPE
3.30
+18450.00%
-0.02
0.00
—
Change In Working Capital
10.21
+204060.00%
0.01
-99.23%
0.65
+106.61%
-9.84
Change In Prepaid Assets
1.68
+301.68%
-0.83
-125.54%
3.27
+1353.33%
0.23
Change In Payables And Accrued Expense
10.93
+387.73%
2.24
-21.37%
2.85
+155.83%
1.11
Change In Other Current Assets
0.00
-100.00%
2.43
+228.72%
-1.89
-161.72%
-0.72
Change In Other Current Liabilities
-2.41
+37.18%
-3.83
-6.89%
-3.58
+65.73%
-10.45
Investing Cash Flow
-48.80
-150.39%
96.86
+36.40%
71.01
+175.47%
-94.09
Cash Flow From Continuing Investing Activities
-48.80
-150.39%
96.86
+36.40%
71.01
+175.47%
-94.09
Net PPE Purchase And Sale
-0.14
+37.99%
-0.23
+78.58%
-1.07
+87.37%
-8.46
Purchase Of PPE
-0.94
-310.92%
-0.23
+78.58%
-1.07
+87.37%
-8.46
Sale Of PPE
0.80
0.00
—
—
Capital Expenditure
-0.94
-310.92%
-0.23
+78.58%
-1.07
+87.37%
-8.46
Net Investment Purchase And Sale
-48.66
-150.12%
97.09
+34.70%
72.08
+184.17%
-85.63
Purchase Of Investment
-53.66
-441.25%
-9.91
+86.77%
-74.92
+39.18%
-123.19
Sale Of Investment
5.00
-95.33%
107.00
-27.21%
147.00
+291.37%
37.56
Financing Cash Flow
503.81
+843.60%
53.39
+1717.29%
2.94
-97.49%
117.14
Cash Flow From Continuing Financing Activities
503.81
+843.60%
53.39
+1717.29%
2.94
-97.49%
117.14
Net Common Stock Issuance
328.21
+487.92%
55.83
+1119.42%
4.58
-96.05%
115.97
Proceeds From Stock Option Exercised
176.93
+163920.37%
-0.11
+88.30%
-0.92
-179.23%
1.17
Net Other Financing Charges
-1.32
+43.01%
-2.33
-224.27%
-0.72
—
Changes In Cash
312.29
+517.31%
50.59
+292.02%
-26.35
+57.57%
-62.09
Beginning Cash Position
84.36
+149.79%
33.77
-43.82%
60.12
-50.81%
122.21
End Cash Position
396.65
+370.18%
84.36
+149.79%
33.77
-43.82%
60.12
Free Cash Flow
-143.65
-43.81%
-99.89
+1.45%
-101.36
-8.28%
-93.61
Amortization Of Securities
-0.07
+94.17%
-1.15
+75.34%
-4.66
-38733.33%
-0.01
Common Stock Issuance
328.21
+487.92%
55.83
+1119.42%
4.58
-96.05%
115.97
Issuance Of Capital Stock
328.21
+487.92%
55.83
+1119.42%
4.58
-96.05%
115.97
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category